As of January 6, 2025, there were six evaluable patients in the Phase 2a arm evaluating IMM-1-104 with modified FOLFIRINOX in ...

COCP READ THE FULL COCP RESEARCH REPORT Business Update Phase 2a Trial of CC-42344 Extended On December 31, 2024, Cocrystal ...

A phase 2a trial of IMM-1-104 plus chemotherapy demonstrated efficacy and tolerability in first- and second-line pancreatic ...

In patients with cancer, HT-001, designed to address skin toxicities, elicited encouraging interim safety and efficacy ...

Immuneering Corporation (IMRX), a Massachusetts-based biopharmaceutical company Monday announced a positive update from its Phase 2a ...

“The data we reported late last year from our IM-PROVE I Phase 2a clinical trial showed a meaningful functional cure rate and immune activation in cHBV patients that were treated with our RNAi ...

Hoth Therapeutics (HOTH) shared encouraging interim safety and efficacy results from its Phase 2a clinical trial of HT-001, designed to address ...

McElhaugh, Interim President and Chief Executive Officer of Arbutus. “The data we reported late last year from our IM-PROVE I Phase 2a clinical trial showed a meaningful functional cure rate and ...

Positive Phase 2a Topline Results for MAR001 “These ... acromegaly in the U.S. Marea expects to initiate a Phase 1 clinical trial with MAR002 in the second half of 2025. Other Corporate ...

The company announced that the first subjects have been dosed in a Phase-1 clinical trial of SUVN-I6107 in the USA.